- Previous Close
1.3200 - Open
1.3100 - Bid --
- Ask --
- Day's Range
1.2500 - 1.3900 - 52 Week Range
0.9230 - 9.2500 - Volume
50,539 - Avg. Volume
1,137,269 - Market Cap (intraday)
1.697M - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-12.6900 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
www.pasithea.comRecent News: KTTA
View MorePerformance Overview: KTTA
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KTTA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KTTA
View MoreValuation Measures
Market Cap
1.70M
Enterprise Value
-10.28M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.11
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.23%
Return on Equity (ttm)
-72.83%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.9M
Diluted EPS (ttm)
-12.6900
Balance Sheet and Cash Flow
Total Cash (mrq)
6.92M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9M